Cargando…
Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: A systematic literature review and pooled analysis
OBJECTIVES: Breast and ovarian cancer account for over 30% of malignant pleural effusions (MPEs). Treatment of the metastatic disease requires control of the MPE. Even though primarily symptomatic, the treatment of the MPE can potentially affect the oncological course of the disease. The aim of this...
Autores principales: | Karampinis, Ioannis, Dionysopoulou, Anna, Galata, Christian, Almstedt, Katrin, Grilli, Maurizio, Hasenburg, Annette, Roessner, Eric D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977169/ https://www.ncbi.nlm.nih.gov/pubmed/35194945 http://dx.doi.org/10.1111/1759-7714.14361 |
Ejemplares similares
-
Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis
por: Jun, Su Youn, et al.
Publicado: (2017) -
Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
por: Li, Zihui, et al.
Publicado: (2023) -
Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis
por: Zhou, Hua, et al.
Publicado: (2017) -
Anaesthetic management of extra-pleural pneumonectomy and hyperthermic intrathoracic chemotherapy procedure
por: Ramegowda, Jalaja Koppa, et al.
Publicado: (2015) -
Surgical cytoreduction and hyperthermic intrathoracic chemotherapy for thymic tumours with pleural spread is effective on survival: results from the multicentre German hyperthermic intrathoracic chemotherapy study
por: Ried, Michael, et al.
Publicado: (2023)